Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001951128 | SCV002239020 | pathogenic | Hereditary nonpolyposis colorectal neoplasms | 2021-03-07 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals with MSH6-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Asn1065Ilefs*13) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). |
Ambry Genetics | RCV002324405 | SCV002609418 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-10-26 | criteria provided, single submitter | clinical testing | The c.3194_3197delACTA pathogenic mutation, located in coding exon 5 of the MSH6 gene, results from a deletion of 4 nucleotides at nucleotide positions 3194 to 3197, causing a translational frameshift with a predicted alternate stop codon (p.N1065Ifs*13). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Laboratory for Genotyping Development, |
RCV003170177 | SCV002758362 | pathogenic | Gastric cancer | 2021-07-01 | no assertion criteria provided | research |